PUBLISHER: IMARC | PRODUCT CODE: 1701891
PUBLISHER: IMARC | PRODUCT CODE: 1701891
The global laser capture microdissection market size reached USD 162 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 346 Million by 2033, exhibiting a growth rate (CAGR) of 8.8% during 2025-2033. The increasing demand for personalized medicines, expanding cancer research, significant growth in biomarker discovery, and advancements in drug development are primarily propelling the market's growth.
Laser capture microdissection (LCM) is a high-resolution method of isolating cells from their surrounding tissues using a laser beam and direct microscopic visualization. It relies on ultraviolet (UV), infrared, and immunofluorescence laser beams to harvest pure enriched cell populations from tissue, blood, and semen samples. It accurately differentiates between normal and abnormal cells to investigate subcellular profiles. It is used on formalin-fixed, paraffin wax-embedded, frozen, and cytologic specimens for studying gene expression and detecting cancer. In addition, it finds application in academic and government research institutes, pharmaceutical and biotechnology companies, polymerase chain reaction (PCR), proteomics, and hospitals for next-generation and sanger sequencing.
The growing utilization of molecular analysis in a bioscience research laboratory, along with the expanding healthcare industry, represents one of the key factors driving the market. Moreover, as LCM allows precise vivo examination of cell populations, such as malignant cells of Hodgkin's disease and carcinoma in situ with sensitive analytical techniques, its sales are rising across the globe. Additionally, there is an increase in healthcare expenditure and research and development (R&D) funding by governments of several countries. This, along with the escalating demand for LCM in forensic science and molecular biology centers to obtain interpretable DNA profiles, is stimulating the market growth. Besides this, LCM is utilized for establishing genetic fingerprints of specific pathological lesions and malignant neoplasms to identify new diagnostic and prognostic markers. It also helps provide individualized treatment of tumor, which is positively influencing the market. Furthermore, key market players are introducing enhanced LCM technologies equipped with immunofluorescence laser diodes for improved biomarker discovery and cancer chemoprevention, which is projected to bolster the growth of the market.
The competitive landscape of the industry has also been examined along with the profiles of the key players being AnaPath Services GmbH (ST Pharm Co. Ltd), Bio-RAD Laboratories Inc., Caresbio Laboratory LLC, Carl Zeiss Meditec AG (Carl Zeiss AG), Epistem Ltd, Fluidigm Corporation, Gnome Diagnostics LLC, HUBNER Photonics, Leica Microsystems GmbH (Danaher Corporation), Molecular Machines & Industries, Thermo Fisher Scientific Inc. and VitroVivo Biotech.